Gastrointestinal, hepatic and pancreatic manifestations of COVID-19 in children

Pegoraro, Francesco; Trapani, Sandra; Indolfi, Giuseppe

doi:10.1016/j.clinre.2021.101818

Cited by 17 publications

(15 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coronavirus disease 2019 (COVID- 19) primarily manifests as a lung infection, with most symptomatic patients presenting with fever, cough and dyspnoea [1 & ]. However, COVID-19 has also significant extrapulmonary complications affecting most organ system [2,3], such as the the central nervous system [4], gastrointestinal tract [5], the cardiovascular system [6] and the skin [7].…”

Section: Introductionmentioning

confidence: 99%

Skin manifestations in patients with coronavirus disease 2019

Bassetti

Massone

Vena

et al. 2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Coronavirus disease 2019 (COVID-19) is a well established respiratory tract illness. Recent studies in adults and children have shown an increasing number of patients reporting polymorphic cutaneous manifestations during COVID-19, including different types of rashes, from maculopapular, vascular, vesicular to atypical forms. Recent findings Although pathogenesis of skin manifestations is still not fully understood, it has been proposed that cutaneous involvement during COVID-19 may be the results of the activation of the immune response against severe acute respiratory syndrome coronavirus-2, the reactivation or co-infection of herpesviruses or drug hypersensitivity. Summary According to available literature, skin manifestations in patients with COVID-19 may be categorized on the basis of their clinical presentations as follows: erythematous rashes, lesions of vascular origin, vesicular rash, urticarial rash and acute generalized exanthematous pustulosis (AGEP), erythema multiforme and other polymorphic erythema/atypical reactions. Prompt recognition of these cutaneous manifestations represents a crucial point to facilitate diagnosis and management of COVID-19 patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Skin manifestations in patients with coronavirus disease 2019

Bassetti

Massone

Vena

et al. 2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Antiplatelet mainly aspirin is continued for four weeks from the outset and sometimes until the coronary arteries become normal. In case of refractory MIS-C where the disease fails to achieve remission, a second dose of IVIG is preferred with pulse doses of IV methylprednisolone (30 mg/kg dose-maximum 1 g daily dose) for three to five days [6]. In our patient, the accomplishment of the recrudescence with the first dose of IVIG was evident so that a second dose was not warranted.…”

Section: Discussionmentioning

confidence: 80%

Diagnosis of Multisystem Inflammatory Syndrome in Children in a Resource-Limited Center

Sekar¹,

Pakkiyaretnam²,

Francis³

2022

Cureus

View full text Add to dashboard Cite

Multisystem inflammatory syndrome in children (MIS-C) has become a serious disease entity following the high prevalence of coronavirus disease 2019 (COVID-19) infection with the involvement of gastrointestinal organs, kidneys, heart, and lungs. When the patient presents with mucocutaneous findings such as conjunctival injection, red lips, neurocognitive symptoms, swollen hands and lymphadenopathy, it is always highly recommended to exclude multisystem inflammatory syndrome.As it affects multiple organs, it can result in more serious consequences. The manifestations depend largely on the organ involved. Therefore, successful management partly depends on the early diagnosis. Many treatment strategies have been put forth to tackle the disorder so far.

show abstract

“…The present findings suggest that acotiamide may be effective for CNVS symptoms that develop after COVID-19. Several reports are available on gastrointestinal COVID-19 symptoms in both adults and children, although it was impossible to definitively determine whether or not the virus was responsible for the nausea in these cases (4). A list of studies demonstrating the association between COVID-19 and gastrointestinal symptoms with functional gastroduodenal disorders is provided in Table 2.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Acotiamide on Nausea as a Symptom of Chronic Nausea and Vomiting Syndrome after Coronavirus Disease 2019

Kakiuchi

Yoshiura

2023

Intern. Med.

View full text Add to dashboard Cite

Chronic nausea and vomiting syndrome (CNVS), one of a functional gastroduodenal disorder, was identified in an 8-year-old girl and a 13-year-old boy who had complained of nausea for more than 4 months following coronavirus disease 2019 (COVID-19) due to normality of their head computed tomography and upper gastrointestinal tract images. The patients' symptoms responded quickly to acotiamide, a medication that is effective for treating functional dyspepsia (FD). Despite being a distinct illness from FD, CNVS is also a functional gastrointestinal disorder, and acotiamide may be just as effective for CNVS following COVID-19 as for FD.

show abstract

Gastrointestinal, hepatic and pancreatic manifestations of COVID-19 in children

Cited by 17 publications

References 114 publications

Skin manifestations in patients with coronavirus disease 2019

Skin manifestations in patients with coronavirus disease 2019

Diagnosis of Multisystem Inflammatory Syndrome in Children in a Resource-Limited Center

The Effect of Acotiamide on Nausea as a Symptom of Chronic Nausea and Vomiting Syndrome after Coronavirus Disease 2019

Contact Info

Product

Resources

About